Nervous System Tumor

New Indication: Dabrafenib and Trametinib in bRAF V600E Mutant Glioma

2022-03-16

  • Study

    Open-label, single-arm, phase 2, basket trial
    BRAFV600E mutation-positive high- low-grade glioma
    Prior radiotherapy and chemotherapy or chemoradiotherapy for high grade glioma
    Dabrafenib 150 mg twice daily plus trametinib 2 mg once daily


  • Efficacy

    High grade glioma; OR: 15/45 patients, CR:3 PR:12
    Low-grade glioma; OR:9/13 patients, CR:1, PR:6, minor response:2


  • Safety

    Grade >=3 AEs: 53%
    Fatigue: 9%, headache: 5%, neutropenia: 5%,


    • Lancet Oncol. 2022; 23(1):53-64.

    Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial

    http://doi.org/10.1016/S1470-2045(21)00578-7

    Reviewed by Hasan Cagri Yildirim, MD on Mar 16, 2022